Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed the exchanges that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for the drug license of one of its stores located on Hosadurga Main Road, Karnataka. The order was issued by the Assistant Director, Drugs Control Administration, Bangalore Circle – Hosadurga, on July 8, 2025, under Rule 65 of the Drugs and Cosmetics Act, 1940. The suspension is for a period of three days. The company has stated a potential revenue loss of approximately Rs 0.69 lakhs (about Rs 69,000) due to this action. The matter is limited to a single store and has a very small financial impact on the overall business.
This is a minor, store-level regulatory issue with negligible financial impact (around Rs 69,000) for Medplus and is unlikely to materially affect the company's operations or stock price. Investors should note it as routine compliance disclosure rather than a significant event.